ANGO übertreffen die 28 der letzten 40Schätzungen.
70%
Nächster Bericht
Datum des nächsten Berichts
31. März 2026
Estimate forQ3 26(Revenue/ EPS)
$78.40M
/
-$0.09
Implizierte Änderung vonQ2 26(Revenue/ EPS)
-1.29%
/
--
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+8.89%
/
-400.00%
AngioDynamics, Inc. earnings per share and revenue
On 06. Jan. 2026, ANGO reported earnings of 0.00 USD per share (EPS) for Q2 26, beating the estimate of -0.10 USD, resulting in a 100.00% surprise. Revenue reached 79.43 million, compared to an expected 77.83 million, with a 2.06% difference. The market reacted with a -13.53% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 78.40 million USD, implying an -- of --% EPS, and decrease of -1.29% in Revenue from the last quarter.
FAQ
What were AngioDynamics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, AngioDynamics, Inc. reported EPS of $0.00, beating estimates by 100%, and revenue of $79.43M, 2.06% above expectations.
How did the market react to AngioDynamics, Inc.'s Q2 2026 earnings?
The stock price moved down -13.53%, changed from $13.23 before the earnings release to $11.44 the day after.
When is AngioDynamics, Inc. expected to report next?
The next earning report is scheduled for 31. März 2026.
What are the forecasts for AngioDynamics, Inc.'s next earnings report?
Based on 6
analysts, AngioDynamics, Inc. is expected to report EPS of -$0.09 and revenue of $78.40M for Q3 2026.